Report : South America Urinalysis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Consumables and Instruments), Test Type (Pregnancy and Fertility Tests, Biochemical Urinalysis, and Sediment Urinalysis), Application (Disease Screening, and Pregnancy and Fertility), and End User (Hospitals and Clinics, Diagnostic Laboratories, Home Care Settings, Research Laboratories, and Institutes)
Sediment Urinalysis Segment is Expected to be Fastest Growing During the Forecast Period for SAM Region to
According to a new market research study on “SAM Urinalysis Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Test Type, Application, End User” is expected to reach US$ 501.91 million by 2028 from 368.45 US$ million in 2021. The market is estimated to grow at a CAGR of 4.5% from 2021 to 2028. The report provides trends prevailing in the SAM urinalysis market along with the drivers and restraints pertaining to the market growth. Developing economies witnessing developments in laboratory infrastructure is the major factor driving the growth of the SAM urinalysis market. However, issues associated with strict government mandates hinders the growth of SAM urinalysis market.
SAM urinalysis market is segmented into product, test type, application, end user, and country. Based on product, the SAM urinalysis market is segmented into consumables and instruments. The consumables segment is expected to hold a larger market share in 2021. The SAM urinalysis market, based on test type, is segmented into pregnancy and fertility tests, biochemical urinalysis, and sediment urinalysis. The biochemical urinalysis segment would hold the largest share of the market in 2021. Based on application, the SAM urinalysis market is segmented into disease screening and pregnancy, and fertility. The disease screening segment would account for a larger market share in 2021. The SAM urinalysis market, by end user, is segmented into hospitals and clinics, diagnostic laboratories, home care settings, and research laboratories and institutes. The hospitals and clinics segment would hold the largest share of the market in 2021. Based on country, the SAM urinalysis market is segmented into Brazil, Argentina, and rest of SAM. Brazil held the largest market share in 2021.
The COVID-19 pandemic had a sudden, dramatic impact on healthcare in SCAM. Hospitals and clinics had to postpone the prescheduled appointments. People hospitalized with COVID-19 were at significant risk of acute kidney damage (AKI), which results in serious illness, dialysis, and even death. Recovered COVID-19 patients with AKI or acute respiratory failure (ARF) were advised to have regular renal examinations due to the risk of developing chronic kidney disease. Women with UTI symptoms such as dysuria, worsening frequency or urgency, and gross hematuria were initially treated by remote communication. COVID-19 had also impacted the regulatory environment and practices as governments and healthcare providers faced unprecedented challenges.
Abbott; ACON Laboratories, Inc.; ARKRAY, Inc.; Beckman Coulter, Inc.; Bio-Rad Laboratories Inc.; Cardinal Health Inc; F. Hoffmann-La Roche Ltd.; Siemens Healthineers AG; and Sysmex Corporation are among the leading companies in the SAM urinalysis market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com